Inhaled corticosteroids are more effective in COPD patients when used with LABA than with SABA

Respiratory Medicine

Volumn 99, Issue 9, 2005, Pages 1115-1124

  Kiri, Victor A ^a,b   Bettoncelli, Germano ^c   Testi, Renato ^d   Viegi, Giovanni ^e  

^a GLAXOSMITHKLINE   (United Kingdom)

^b LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^c Italian Society of General Medicine SIMG   (Italy)

^d GSK   (Italy)

^e INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

Author keywords

COPD; Inhaled corticosteroids; Long acting beta agonists; Mortality; Re hospitalization; Short acting beta agonists

Indexed keywords

ANTIHISTAMINIC AGENT; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CHOLINERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; OXYGEN; STEROID; XANTHINE DERIVATIVE;

ADULT; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DATA BASE; DEATH; DISEASE SEVERITY; DRUG EFFICACY; DRUG UTILIZATION; EXPERIENCE; FEMALE; GENERAL PRACTICE; HOSPITAL DISCHARGE; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE ANALYSIS; PRESCRIPTION; PRIORITY JOURNAL; RISK REDUCTION; SURVIVAL RATE; TREATMENT OUTCOME; UNITED KINGDOM;

ADMINISTRATION, INHALATION; ADRENERGIC BETA-AGONISTS; AGED; AGED, 80 AND OVER; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; MALE; MIDDLE AGED; PATIENT READMISSION; PRESCRIPTIONS, DRUG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; RETROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 23344435582     PISSN: 09546111     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.rmed.2005.02.018     Document Type: Article

References (44)

1. Murray CJL, Lopez AD, Mathers CD, Stein C. The global burden of disease 2000 project: Aims, methods and data sources. Global Programme on Evidence for Health Policy Discussion Paper No. 36, World Health Organization, November 2001.
2. M. Friedman D.E. Hilleman Economic burden of chronic obstructive pulmonary disease. Impact of new treatment options Pharmacoeconomics 19 2001 245-254
3. LAIA: Lung & Asthma Information Agency. Trends in emergency hospital admissions for lung disease. Factsheet 99/2, St. George's Hospital Medical School.
4. G. Viegi A. Scognamiglio S. Baldacci F. Pistelli L. Carrozzi Epidemiology of chronic obstructive pulmonary disease (COPD) Respiration 68 2001 4-19
5. Viegi G. Epidemiology of COPD: A European perspective. In: Burney P, Suissa S, Soriano JB, editors. In the pharmacoepidemiology of COPD: recent advances and methodological discussion; Eur Respir J. 2003;22(Suppl. 43):3-7.
6. R. Dal Negro P. Berto S. Tognella L. Quareni Global outcomes in Lung Disease Study Group. Cost-of-illness of lung disease in the TriVeneto Region, Italy: The GOLD Study Monaldi Arch Chest Dis 57 2002 3-9
7. F. Andersson S. Borg S.A. Jansson et al. The costs of exacerbations in chronic obstructive pulmonary disease (COPD) Respir Med 96 2002 700-708
8. P.S. Burge P.M. Calverley P.W. Jones S. Spencer J.A. Anderson T.K. Maslen Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: The ISOLDE trial Br Med J 320 2000 1297-1303
9. The Lung Health Study Research Group. Effect of inhaled triamcinolone on the decline in pulmonary function in chronic obstructive pulmonary disease. N Engl J Med 2000;343.
10. D.D. Sin J.V. Tu Inhaled corticosteroids and the risk of mortality and readmission in elderly patients with chronic obstructive pulmonary disease Am J Respir Crit Care Med 164 2001 580-584
11. D.D. Sin S.F.P. Man Inhaled corticosteroids and survival in chronic obstructive pulmonary disease: Does the dose matter? Eur Respir J 21 2003 260-266
12. B.R. Celli W. MacNee committee members Standards for the diagnosis and treatment of patients with COPD: A summary of the ATS/ERS position paper Eur Respir J 23 2004 932-946
13. C. O'Brien P.J. Guest S.L. Hill R.A. Stockley Physiological and radiological characterisation of patients diagnosed with chronic obstructive pulmonary disease in primary care Thorax 55 2000 635-642
14. P. Calverley R. Pauwels J. Vesbo et al. for the TRISTAN Study Group Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: A randomised controlled trial Lancet 361 2003 449-456
15. J.B. Soriano J. Vestbo N.B. Pride V. Kiri C. Maden Maier WC survival of COPD patients after regular use of fluticasone propionate salmeterol in primary care in the UK Eur Respir J 20 2002 819-825
16. J.B. Soriano V.A. Kiri N.B. Pride J. Vesto Inhaled corticosteroids with/ without long-acting beta-agonist reduce the risk of re-hospitalization and death in COPD patients Am J Respir Med 2 2003 67-74
17. D.H. Lawson V. Sherman J. Hollowell The general practice research database. Scientific and Ethical Advisory Group Q J Med 91 1998 445-452
18. H. Jick S.S. Jick L.E. Derby Validation of information recorded on general practitioner based computerised data resources in the UK Br Med J 302 1991 766-768
19. L.A. Garcia Rodriguez S. Perez Gutthann Use of the UK General Practice Research Database for pharmacoepidemiology Br J Clin Pharmacol 45 1998 419-425
20. I. Nazareth M. King A. Haines L. Rangel S. Myers Accuracy of diagnosis on general practice computer system Br Med J 307 1993 32-34
21. A. Hansell J. Hollowell T. Nichols R. McNiece D. Strachan Use of the General Practice Research Database (GPRD) for respiratory epidemiology: a comparison with the 4th Morbidity Survey in General Practice (MSGP4) Thorax 54 1999 413-419
22. J.B. Soriano W.C. Maier P. Egger et al. Recent trends of physician-diagnosed COPD in women and men in the UK Thorax 55 2000 789-794
23. K.J. Rothman S. Greenland Modern epidemiology 1998 Lippincott-Raven Publishers Philadelphia
24. S. Suissa Effectiveness of inhaled corticosteroids in chronic obstructive pulmonary disease Am J Respir Crit Care Med 168 2003 49-53
25. K.J. Rothman A potential bias in safety evaluation during open-label extensions of randomized clinical trials Pharmacoepidemiol Drug Saf 13 2004 295-298
26. R.B. D'Agostino Tutorial in biostatistics - propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group Stat Med 17 1998 2265-2281
27. S.V. Morant D. Pettitt T.M. MacDonald T.A. Burke J.L. Goldstein Application of propensity score to adjust for channelling bias with NSAIDS Pharmacoepidemiology and drug safety 13 2004 345-353
28. J.P. Frolkis C.E. Pthier E.H. Blackstone M.S. Lauder Frequent ventricular ectopy after exercise as a predictor of death N Engl J Med 348-349 2003
29. G.E. Silva D.L. Sherrill S. Guerra R.A. Barbee Asthma as a risk factor for COPD in a longitudinal study Thorax 126 2004 59-65
30. A.M. Schols G. Wesseling A.D. Kester et al. Dose dependent increased mortality risk in COPD patients treated with oral glucocorticoids Eur Respir J 17 2001 337-342
31. R.A. Deyo D.C. Cherkin M.A. Ciol Adapting a clinical comorbidity index for use with ICD-9-CM administrative databases J Clin Epidemiol 45 1992 613-619
32. C.J.L. Murray A.D. Lopez Alternative projections of mortality and disability by cause 1990-2020 Lancet 349 1997 1498-1504
33. P.J. Barnes Inhaled steroids are not beneficial in COPD Am J Respir Crit Care Med 161 2000 342-344
34. E.R. Sutherland H. Allmers N.T. Ayas A.J. Venn R.J. Martin Inhaled corticosteroids reduce the progression of airflow limitation in chronic obstructive pulmonary disease: A meta-analysis Thorax 58 2003 937-941
35. P.M. Calverley Inhaled steroids are beneficial in COPD Am J Respir Crit Care Med 161 2000 341-342
36. A. Alsaeedi D.D. Sin F.A. McAlister The effects of inhaled corticosteroids in chronic obstructive pulmonary disease: A systematic review of randomized placebo-controlled trials Am J Med 113 2002 59-65
37. P.J. Barnes Scientific rationale for inhaled combination therapy with long-acting B2-agonists and corticosteroids Eur Respir J 19 2002 182-191
38. J.B. Soriano W.C. Maier G. Visick N. Pride Validation of general practitioner-diagnosed COPD in the UK General Practice Research Database Eur J Epidemiol 17 2001 1075-1080
39. C. Cricelli G. Mazzaglia F. Samani et al. Prevalence estimates fro chronic diseases in Italy: Exploring the differences between self-report and primary care databases J Public Health Med 25 3 2003 254-257
40. A. Filippi S. Buda O. Brignoli C. Cricelli E.D. Esposti Global cardiovascular risk evaluation in Italy: A cross-sectional survey in general practice Ital Heart J 5 3 2004 223-227
41. A. Filippi A.A. Bignamini E. Sessa F. Samani G. Mazzaglia Secondary prevention of stroke in Italy: A cross-sectional survey in family practice Stroke 34 2003 1010-1014
42. G. Mazzaglia A.P. Caputi A. Rossi G. Bettoncelli G. Stefanini G. Ventriglia R. Nardi O. Brignoli C. Cricelli Exploring patient- and doctor-related variables associated with antibiotic prescribing for respiratory infections in primary case Eur J Clin Pharmacol 59 2003 651-657
43. B.L. Strom Pharmacoepidemiology 3rd ed 2000 Wiley Chichester
44. J. Vesbo Another piece of the inhaled corticosteroids in COPD puzzle Am J Respir Crit Care Med 164 2001 315-514